Standard BioTools

Standard BioTools Shares Outstanding

The The number of shares of Standard BioTools (LAB) as of Nov 5, 2026 is 384.57 M. In the previous year, The number of shares was 384.57 M — a change of 0.00% (lower).

Shares Outstanding

384.57 M

YoY

0.00%

Last updated:

In 2025, Standard BioTools had 384.57 M outstanding stocks, a 0.00% change from the 384.57 M stocks in the previous year.

The Standard BioTools Shares Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Shares Outstanding
Date
Shares Outstanding
Jan 1, 2022
384.57 M USD
Jan 1, 2023
384.57 M USD
Jan 1, 2024
384.57 M USD
Jan 1, 2025
384.57 M USD
Jan 1, 2026 (e)
385.05 USD
Jan 1, 2027 (e)
385.05 USD
Jan 1, 2028 (e)
385.05 USD
Jan 1, 2029 (e)
385.05 USD
The Standard BioTools Shares Outstanding history
YEARShares OutstandingYoY
est385.050.00%
est385.050.00%
est385.050.00%
est385.05-100.00%
384.57 M0.00%
384.57 M0.00%
384.57 M0.00%
384.57 M0.00%
384.57 M0.00%
384.57 M0.00%
384.57 M0.00%
384.57 M0.00%
384.57 M0.00%
384.57 M0.00%
384.57 M0.00%
384.57 M+1.50 B%
25.70+2.67%
25.03+22.72%
20.39+89.64%
10.75+477.86%
1.86+12.58%
1.65-12.54%
1.890.00%
1.89—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Standard BioTools Number of shares

Standard BioTools shares outstanding

The number of shares of Standard BioTools was 385.05 M in 2025. This indicates how many shares Standard BioTools is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2022
79.43 M Stocks
Jan 1, 2023
79.73 M Stocks
Jan 1, 2024
374.54 M Stocks
Jan 1, 2025
385.05 M Stocks
Jan 1, 2026 (e)
385.05 M Stocks
Jan 1, 2027 (e)
385.05 M Stocks
Jan 1, 2028 (e)
385.05 M Stocks
Jan 1, 2029 (e)
385.05 M Stocks

Standard BioTools Stock analysis

What does Standard BioTools do? Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools is one of the most popular companies on Eulerpool.

Shares Outstanding Details

Evaluating Standard BioTools's Shares Outstanding

Standard BioTools's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Standard BioTools’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Standard BioTools’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Standard BioTools’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Standard BioTools stock

The number of shares of Standard BioTools is 384.57 M in 2025.

The number of shares of Standard BioTools changed from 384.57 M to 384.57 M, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The number of shares Standard BioTools since 2006 – with annual values, charts, and detailed analysis.

The number of shares indicates the total number of a company's shares. This includes not only the shares available on the market, but also the shares held by shareholders and the shares retained by the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Standard BioTools

All Key Metrics — Standard BioTools